1. Home
  2. ELTX vs INCR Comparison

ELTX vs INCR Comparison

Compare ELTX & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$5.27

Market Cap

58.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
INCR
Founded
2011
1994
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
58.6M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ELTX
INCR
Price
$2.05
$5.27
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
281.3K
28.5K
Earning Date
05-12-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
39.29
N/A
EPS
N/A
N/A
Revenue
$2,301,000.00
N/A
Revenue This Year
N/A
$69.54
Revenue Next Year
N/A
$41.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$0.68
52 Week High
$16.00
$6.10

Technical Indicators

Market Signals
Indicator
ELTX
INCR
Relative Strength Index (RSI) 22.25 75.60
Support Level N/A $0.84
Resistance Level $3.32 $6.10
Average True Range (ATR) 0.13 0.29
MACD -0.04 0.00
Stochastic Oscillator 4.33 83.80

Price Performance

Historical Comparison
ELTX
INCR

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

Share on Social Networks: